NAMSWNewAmsterdam Pharma Company N.V. Warrant
16.51USDMkt Cap: —P/E: —4d ago
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)7.12M $
Gross Profit7.12M $
Net Income (TTM)-203.82M $
Revenue/Share0.0590 USD
Last Price16.51 USD
Fiscal Year End—
MR Quarter—
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.08
EPS (TTM)—
EPS (Forward)—
52W Range
—
52W High16.51 USD
52W Low16.51 USD
Profitability
Gross Margin100.00%
Oper. Margin-1752.61%
EBITDA Margin0.00%
Profit Margin-905.74%
ROE-29.82%
ROA-26.49%
Growth
Revenue Growth-80.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-147.78M $
CapEx (TTM)246.00K $
FCF Margin-636.97%
FCF Yield—
Net Debt-633.77M $
Net Debt/EBITDA2.60
Balance Sheet
Debt/Equity0.00
Current Ratio9.03
Quick Ratio8.76
Book Value/Sh5.367 USD
Cash/Share5.303 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float82.90M
Insiders—
Institutions—
Technical
SMA 5019.35 (-14.7%)
SMA 20022.37 (-26.2%)
Beta0.11
S&P 52W Chg21.00%
Avg Vol (30d)200
Avg Vol (10d)5.00K
Technical Indicators
RSI (14)41.0
MACD-0.9337
MACD Signal-1.1046
MACD Hist.+0.1709
BB Upper18.36 USD
BB Middle16.58 USD
BB Lower14.80 USD
BB Width21.45%
ATR (14)0.6561 USD
Vol Ratio (20d)0.00x